<DOC>
	<DOCNO>NCT01003938</DOCNO>
	<brief_summary>This single arm phase II study combination Hycamptin® ( topotecan ) erlotinib minimum 2 cycle patient ( 18 yrs age old ) recurrent ovarian cancer previously treat chemotherapy drug Hycamptin® ( topotecan ) . Up 30 patient enrol study .</brief_summary>
	<brief_title>Topotecan With Erlotinib Topotecan Pretreated Ovarian Cancer</brief_title>
	<detailed_description>On Day 1 treatment cycle , topotecan 0.4 mg/m^2/day administer via continuous infusion 9 day begin Day 1 every 21 day cycle . Additionally , patient receive erlotinib 150 mg daily Days 1-9 cycle 21 day . Thereafter drug give long patient benefit continue . Treatment administer inpatient outpatient basis , repeat administration every 3 week cycle . A cycle one three-week course erlotinib-topotecan regimen ( cycle could extend 4 week blood study 21 day result treatment delay ) . The dose topotecan calculate follow : BSA ( m^2 ) X drug dose ( mg/m^2 ) = dose ( mg )</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>1 . Histologically cytologically proven , previously treat , epithelial ovarian cancer , and/or serous ovarian cancer . 2 . Evaluable disease CA125 level two time upper limit normal institution ( &gt; 50u/ml ) two occasion least one week apart require order apply CA125 response criterion . 3 . Previously treat ovarian cancer taxane platinum base regimen . additional topotecan regimen ( number chemotherapy biologic therapy allow ; include prior erlotinib allow ) 4 . Age &gt; = 18 year . 5 . Minimum life expectancy : 4 month . 6 . ECOG ( Eastern Cooperative Oncology Group ) performance status 0,1 , 2 . 0 : Fully active , unrestricted activity daily live . 1 : Ambulatory , restrict strenuous activity . 2 : Ambulatory , capable self care . Unable work . Out bed great 50 % waking hour . 7 . Complete blood count ( CBC ) perform less seven day prior enrollment absolute neutrophil count &gt; 1.0 X 10^9/L , platelet count &gt; 100 X 10^9/L . 8 . Serum chemistry panel drawn less seven day prior enrollment total bilirubin &lt; = 1.5 X institutional upper limit normal ( IULN ) , SGOT/AST &lt; 2.5 X IULN . 9 . Serum creatinine &lt; = 1.5 X institutional upper limit normal ( IULN ) . If serum creatinine level &gt; = 1.5 IULN , serum creatinine clearance &gt; = 50 mg/dL , subject enter study . 10 . Central line access . 11 . Signed write inform consent ( approved Institutional Review Board [ IRB ] /Ethics Committee ) obtain prior study entry . If answer exclusion criterion YES , subject NOT ELIGIBLE study . 1 . Presence active cancer describe Section 3.1.criteria ( ) , exception diagnosis synchronous occurrence adenocarcinoma ovary uterus . 2 . Uncontrolled intercurrent illness limited infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia . 3 . Acute toxicity prior chemotherapy still present 4 . History severe allergic reaction erlotinib 5 . Unresolved sequelae result surgical procedure . 6 . Symptomatic , untreated brain metastasis . Patients untreated brain metastasis exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event . 7 . Lactating pregnant . The investigational agent topotecan may toxic develop fetus nursing infant pose unknown health risk . Documentation negative , serum HCG pregnancy test require woman child bear potential ( WOCBP ) within 2 week prior start treatment . WOCBP define woman naturally postmenopausal least 12 consecutive month previous surgical sterilization . A negative pregnancy test within 2 week prior start treatment require . 8 . Women childbearing potential must use effective contraception throughout time study . Before enter trial , patient must make aware risk become pregnant . 9 . Receipt investigational drug within 28 day begin treatment study drug and/or concomitant treatment investigational agent . 10 . Patients history poorly control gastrointestinal disorder could affect absorption erlotinib ( e.g . Crohn 's , ulcerative colitis , etc )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>chemotherapy</keyword>
	<keyword>combination therapy</keyword>
	<keyword>target therapy</keyword>
	<keyword>second-line</keyword>
</DOC>